# Thermo Fisher (TMO) — Earnings TMO · NYSE · Stock Canonical page: https://www.lighthorse.io/tickers/tmo/earnings ## Most recent quarter | Metric | Value | | --- | --- | | Fiscal period | Q2 2026 | | Period end | Jun 27, 2026 | | EPS actual | $6.03 | | EPS estimate | $5.72 | | EPS surprise | +5.43% | | Revenue surprise | +2.46% | | Revenue | $12.0B | | Revenue estimate | $11.7B | | Reported | Jul 23, 2026 | | SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/97745/000009774526000144/tmo-20260627.htm) | | Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/db399e3c-7d22-7258-4642-06420b38c5a7.html) | Thermo Fisher reported Q2 2026 results on July 23, 2026. Earnings per share were $6.03, ahead of the $5.72 estimate by 5.43%. Revenue was $12.0 billion, 2.46% above the $11.7 billion consensus. Compared with Q2 2025, EPS rose about 13% from $5.36 and revenue rose about 10% from $10.9 billion. The longer record shows a dip and a gradual climb. Annual EPS fell from $23.24 in 2022 to $21.54 in 2023, then rose to $21.86 in 2024 and $22.87 in 2025. The first two quarters of 2026 add up to $11.47, about 9% more than the same period a year earlier. The highest quarterly EPS in the table is still Q1 2022's $7.25. Revenue peaked at $12.2 billion in Q4 2025. Over the last 20 quarters, Thermo Fisher topped the EPS estimate 19 times. The only miss was Q2 2023, at 5.03% below. Most recent beats have been modest, under 6% in each quarter since 2024 except Q1 2024. Thermo Fisher reported Q3 between October 22 and October 27 in each of the past five years. That points to late October 2026 for the next report. It will show whether the year-over-year growth of the first half of 2026 continued. ## Earnings history | Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual | | --- | --- | --- | --- | --- | --- | --- | | Q2 2026 | Jul 23, 2026 | $5.72 | $6.03 | 5.43% | $11.7B | $12.0B | | Q1 2026 | Apr 23, 2026 | $5.25 | $5.44 | 3.65% | $10.9B | $11.0B | | Q4 2025 | Jan 29, 2026 | $6.45 | $6.57 | 1.88% | $11.9B | $12.2B | | Q3 2025 | Oct 22, 2025 | $5.50 | $5.79 | 5.32% | $10.9B | $11.1B | | Q2 2025 | Jul 23, 2025 | $5.23 | $5.36 | 2.56% | $10.7B | $10.9B | | Q1 2025 | Apr 23, 2025 | $5.10 | $5.15 | 0.95% | $10.2B | $10.4B | | Q4 2024 | Jan 30, 2025 | $5.94 | $6.10 | 2.66% | $11.3B | $11.4B | | Q3 2024 | Oct 23, 2024 | $5.24 | $5.28 | 0.72% | $10.6B | $10.6B | | Q2 2024 | Jul 24, 2024 | $5.12 | $5.37 | 4.87% | $10.5B | $10.5B | | Q1 2024 | Apr 24, 2024 | $4.71 | $5.11 | 8.52% | $10.2B | $10.3B | | Q4 2023 | Jan 31, 2024 | $5.64 | $5.67 | 0.46% | $10.7B | $10.9B | | Q3 2023 | Oct 25, 2023 | $5.61 | $5.69 | 1.39% | $10.6B | $10.6B | | Q2 2023 | Jul 26, 2023 | $5.42 | $5.15 | -5.03% | $11.0B | $10.7B | | Q1 2023 | Apr 26, 2023 | $5.03 | $5.03 | 0.04% | $10.7B | $10.7B | | Q4 2022 | Feb 1, 2023 | $5.20 | $5.40 | 3.92% | $10.4B | $11.4B | | Q3 2022 | Oct 26, 2022 | $4.83 | $5.08 | 5.09% | $9.9B | $10.7B | | Q2 2022 | Jul 28, 2022 | $4.99 | $5.51 | 10.47% | $10.0B | $11.0B | | Q1 2022 | Apr 28, 2022 | $6.22 | $7.25 | 16.61% | $10.7B | $11.8B | | Q4 2021 | Feb 2, 2022 | $4.93 | $6.54 | 32.74% | $8.7B | $10.7B | | Q3 2021 | Oct 27, 2021 | $4.68 | $5.76 | 23.02% | $8.4B | $9.3B | ## Frequently Asked Questions ### When did Thermo Fisher (TMO) last report earnings? Thermo Fisher last reported on Jul 23, 2026, covering fiscal Q2 2026. ### Did TMO beat earnings estimates? Yes. Thermo Fisher reported EPS of $6.03 for Q2 2026 against a $5.72 estimate — a 5.43% beat. ### How much revenue did TMO report last quarter? Thermo Fisher reported $12.0B in revenue for Q2 2026, against a consensus estimate of $11.7B. ## Similar Stocks - [WST](https://www.lighthorse.io/tickers/wst) — West Pharmaceutical Services, Inc. Common Stock - [MEDP](https://www.lighthorse.io/tickers/medp) — Medpace Holdings, Inc. - Common Stock - [MCK](https://www.lighthorse.io/tickers/mck) — McKesson Corporation Common Stock - [AMN](https://www.lighthorse.io/tickers/amn) — AMN Healthcare Services Inc - [BIO](https://www.lighthorse.io/tickers/bio) — Bio-Rad Laboratories, Inc. Class A Common Stock - [A](https://www.lighthorse.io/tickers/a) — Agilent Technologies, Inc. Common Stock - [DHR](https://www.lighthorse.io/tickers/dhr) — Danaher Corporation Common Stock - [QGEN](https://www.lighthorse.io/tickers/qgen) — Qiagen N.V. Common Shares - [BIO.B](https://www.lighthorse.io/tickers/bio.b) — Bio-Rad Laboratories, Inc. Class B Common Stock - [ILMN](https://www.lighthorse.io/tickers/ilmn) — Illumina, Inc. - Common Stock --- Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance. This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness. Data provided by [AInvest](https://www.ainvest.com).